JP2014159478A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014159478A5 JP2014159478A5 JP2014111127A JP2014111127A JP2014159478A5 JP 2014159478 A5 JP2014159478 A5 JP 2014159478A5 JP 2014111127 A JP2014111127 A JP 2014111127A JP 2014111127 A JP2014111127 A JP 2014111127A JP 2014159478 A5 JP2014159478 A5 JP 2014159478A5
- Authority
- JP
- Japan
- Prior art keywords
- biological system
- animal
- seq
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65347905P | 2005-02-16 | 2005-02-16 | |
| US60/653,479 | 2005-02-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011264338A Division JP5852426B2 (ja) | 2005-02-16 | 2011-12-02 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016183644A Division JP6250764B2 (ja) | 2005-02-16 | 2016-09-21 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014159478A JP2014159478A (ja) | 2014-09-04 |
| JP2014159478A5 true JP2014159478A5 (enExample) | 2014-11-13 |
| JP6073833B2 JP6073833B2 (ja) | 2017-02-01 |
Family
ID=36917026
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007556264A Expired - Fee Related JP5063366B2 (ja) | 2005-02-16 | 2006-02-16 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
| JP2011264338A Expired - Fee Related JP5852426B2 (ja) | 2005-02-16 | 2011-12-02 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
| JP2014111127A Expired - Fee Related JP6073833B2 (ja) | 2005-02-16 | 2014-05-29 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
| JP2016183644A Expired - Fee Related JP6250764B2 (ja) | 2005-02-16 | 2016-09-21 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007556264A Expired - Fee Related JP5063366B2 (ja) | 2005-02-16 | 2006-02-16 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
| JP2011264338A Expired - Fee Related JP5852426B2 (ja) | 2005-02-16 | 2011-12-02 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016183644A Expired - Fee Related JP6250764B2 (ja) | 2005-02-16 | 2016-09-21 | ヘプシジンによる鉄代謝を制御するためのＴＧＦ−βスーパーファミリーの化合物の調節因子の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US7968091B2 (enExample) |
| EP (3) | EP2954903A1 (enExample) |
| JP (4) | JP5063366B2 (enExample) |
| CA (1) | CA2597925A1 (enExample) |
| ES (2) | ES2547866T3 (enExample) |
| HK (1) | HK1218875A1 (enExample) |
| WO (1) | WO2006088972A2 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002231736A1 (en) | 2000-12-22 | 2002-07-08 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Use of repulsive guidance molecule (rgm) and its modulators |
| EP2186524B1 (en) * | 2001-05-25 | 2018-02-21 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| EP2954903A1 (en) * | 2005-02-16 | 2015-12-16 | The General Hospital Corporation | Use of bmp antagonists to regulate hepcidin-mediated iron metabolism |
| US20070099245A1 (en) * | 2005-09-29 | 2007-05-03 | Boris Gorovits | Assays for neutralizing antibodies |
| CN101277974A (zh) | 2005-09-30 | 2008-10-01 | 阿伯特有限及两合公司 | 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途 |
| BRPI0618947B1 (pt) | 2005-11-23 | 2022-07-19 | Acceleron Pharma Inc | Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CA2672758C (en) | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| TWI584815B (zh) | 2007-02-01 | 2017-06-01 | 艾瑟勒朗法瑪公司 | 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途 |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| MX2009008510A (es) | 2007-02-09 | 2010-01-15 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer. |
| WO2008124768A1 (en) * | 2007-04-09 | 2008-10-16 | The General Hospital Corporation | Hemojuvelin fusion proteins and uses thereof |
| CA2699936A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| CA2742871C (en) * | 2008-11-13 | 2018-10-23 | Herb Lin | Methods and compositions for regulating iron homeostasis by modulation of bmp-6 |
| US20110293526A1 (en) * | 2008-11-20 | 2011-12-01 | University Of Southern California | Compositions and methods to modulate hair growth |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| MX355042B (es) | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| PH12012501070A1 (en) | 2009-12-08 | 2017-08-23 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
| CA2817008A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
| KR102035357B1 (ko) * | 2011-01-19 | 2019-10-23 | 페루맥스 파마수티컬스, 인코포레이티드 | 철 항상성을 조절하기 위한 조성물 및 이의 사용 방법 |
| MX357708B (es) | 2011-12-14 | 2018-07-20 | Abbvie Deutschland | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. |
| CN104136462B (zh) * | 2011-12-14 | 2017-06-09 | 艾伯维德国有限责任两合公司 | 用于诊断和治疗铁相关病症的组合物和方法 |
| AU2013211939C1 (en) | 2012-01-27 | 2018-06-07 | AbbVie Deutschland GmbH & Co. KG | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
| CA2890040A1 (en) * | 2012-11-01 | 2014-05-08 | The Regents Of The University Of California | Erythroferrone and erfe polypeptides and methods of regulating iron metabolism |
| RU2678117C2 (ru) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| AR093620A1 (es) | 2012-12-17 | 2015-06-10 | Lilly Co Eli | Anticuerpos bmp-6 |
| US20160051556A1 (en) * | 2013-03-21 | 2016-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression |
| CN105659087B (zh) * | 2013-06-13 | 2019-09-17 | 比奥德赛公司 | 筛选靶向靶生物实体的候选生物实体的方法 |
| HK1225742A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| EP3227675B1 (en) | 2014-12-03 | 2023-03-15 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
| UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
| EP3237906B8 (en) | 2014-12-23 | 2020-10-28 | Bluelight Therapeutics, Inc. | Attachment of proteins to interfaces for use in nonlinear optical detection |
| EP3307070B1 (en) | 2015-06-12 | 2025-10-29 | Emory University | Growth and survival compositions for cells capable of producing antibodies and methods related thereto |
| US20200231652A1 (en) | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| WO2017068089A2 (en) * | 2015-10-23 | 2017-04-27 | Vifor (International) Ag | Novel ferroportin inhibitors |
| WO2017147078A1 (en) | 2016-02-22 | 2017-08-31 | Brigham Young University | Method and compositions for the treatment of anemia through the inhibition of furin |
| WO2017216724A1 (en) | 2016-06-15 | 2017-12-21 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6) |
| IL268995B2 (en) | 2017-03-02 | 2024-02-01 | Nat Res Council Canada | TGF-B receptor ectodomain fusion compounds and their uses |
| US11125757B2 (en) | 2017-05-26 | 2021-09-21 | Emory University | Methods of culturing and characterizing antibody secreting cells |
| CA3117695A1 (en) | 2018-10-26 | 2020-04-30 | Keros Therapeutics, Inc. | Crystal forms of an alk2 inhibitor |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| US20220372136A1 (en) * | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating anemia of chronic disease |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| WO2022098821A1 (en) * | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating lymphopenia |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| DK0414297T3 (da) | 1989-08-11 | 1997-07-07 | Genencor Int | Effektiv fremstilling af mutantproteaser |
| US5830847A (en) | 1992-10-30 | 1998-11-03 | Hsc Research & Development Limited Partnership | Soluble TGF-β-binding endoglin polypeptides and homodimers |
| WO1994024314A1 (en) | 1993-04-19 | 1994-10-27 | Kauffman Stuart A | Random chemistry for the generation of new compounds |
| JPH09508353A (ja) | 1993-11-02 | 1997-08-26 | アフィマックス テクノロジーズ ナムローゼ フェンノートシャップ | 分子多様性の合成及びスクリーニング |
| WO1998033918A1 (en) | 1997-02-05 | 1998-08-06 | The Regents Of The University Of California | Morphogenic proteins |
| WO2001054708A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | 22 human secreted proteins |
| EP1130094A3 (en) | 1999-07-08 | 2001-11-21 | Helix Research Institute | Primers for synthesizing full length cDNA clones and their use |
| WO2002077006A1 (en) | 2001-03-23 | 2002-10-03 | Human Genome Sciences, Inc. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| US6800455B2 (en) | 2000-03-31 | 2004-10-05 | Scios Inc. | Secreted factors |
| CN1159063C (zh) * | 2000-06-21 | 2004-07-28 | 中国医学科学院血液学研究所 | 骨形态发生蛋白（bmp）作为治疗急性再生障碍性贫血药物的应用 |
| AU2002231736A1 (en) | 2000-12-22 | 2002-07-08 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Use of repulsive guidance molecule (rgm) and its modulators |
| EP2186524B1 (en) * | 2001-05-25 | 2018-02-21 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
| WO2003000461A1 (fr) | 2001-06-21 | 2003-01-03 | Meiyu-Giken Co., Ltd. | Procede de polissage de la surface d'extremite de connexion d'un connecteur a fibres optiques, structure optique et structure heterogene coaxiale de couches de materiau, et dispositif de polissage |
| WO2003004615A2 (en) | 2001-07-05 | 2003-01-16 | Incyte Genomics, Inc. | Secreted proteins |
| JP2003135075A (ja) | 2001-11-05 | 2003-05-13 | Research Association For Biotechnology | 新規な全長ｃＤＮＡ |
| WO2003089608A2 (en) | 2002-04-18 | 2003-10-30 | The General Hospital Corporation | Drg11-responsive (dragon) gene family |
| CA2542171C (en) | 2002-06-26 | 2015-12-15 | Abbott Gmbh & Co. Kg | Modulators and modulation of the interaction between rgm and neogenin |
| DE10230381A1 (de) * | 2002-07-05 | 2004-01-22 | Institut für Medizintechnologie Magdeburg GmbH, IMTM | Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen |
| GB0217786D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| EP1618131A2 (en) | 2003-04-15 | 2006-01-25 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
| WO2005028517A2 (en) | 2003-05-09 | 2005-03-31 | The General Hospital Corporation | SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS |
| US20060063208A1 (en) | 2004-08-02 | 2006-03-23 | Woolf Clifford J | DRG11-responsive (DRAGON) gene and uses thereof |
| EP2954903A1 (en) * | 2005-02-16 | 2015-12-16 | The General Hospital Corporation | Use of bmp antagonists to regulate hepcidin-mediated iron metabolism |
| CA2549477A1 (en) | 2005-06-29 | 2006-12-29 | The Regents Of The University Of California | Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin |
-
2006
- 2006-02-16 EP EP15173396.1A patent/EP2954903A1/en not_active Withdrawn
- 2006-02-16 JP JP2007556264A patent/JP5063366B2/ja not_active Expired - Fee Related
- 2006-02-16 ES ES10196139.9T patent/ES2547866T3/es not_active Expired - Lifetime
- 2006-02-16 WO PCT/US2006/005367 patent/WO2006088972A2/en not_active Ceased
- 2006-02-16 CA CA002597925A patent/CA2597925A1/en not_active Abandoned
- 2006-02-16 ES ES06735151T patent/ES2392096T3/es not_active Expired - Lifetime
- 2006-02-16 EP EP10196139.9A patent/EP2335719B1/en not_active Expired - Lifetime
- 2006-02-16 US US11/884,509 patent/US7968091B2/en active Active
- 2006-02-16 EP EP06735151A patent/EP1858541B1/en not_active Revoked
-
2011
- 2011-06-28 US US13/171,438 patent/US8293236B2/en not_active Expired - Fee Related
- 2011-12-02 JP JP2011264338A patent/JP5852426B2/ja not_active Expired - Fee Related
-
2012
- 2012-02-28 US US13/407,502 patent/US8637023B2/en not_active Expired - Fee Related
- 2012-10-18 US US13/654,623 patent/US8865168B2/en not_active Expired - Lifetime
-
2014
- 2014-05-29 JP JP2014111127A patent/JP6073833B2/ja not_active Expired - Fee Related
- 2014-07-16 US US14/332,716 patent/US9556251B2/en not_active Expired - Fee Related
-
2016
- 2016-06-16 HK HK16106934.8A patent/HK1218875A1/en unknown
- 2016-09-21 JP JP2016183644A patent/JP6250764B2/ja not_active Expired - Fee Related
- 2016-12-12 US US15/375,491 patent/US20170183411A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Underwood et al. | Biology and diseases of ruminants (sheep, goats, and cattle) | |
| JP2013172734A5 (enExample) | ||
| NZ629261A (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| HRP20210057T1 (hr) | Presađivanje stem stanica s kombinacijom sredstva koje cilja stem stanice i modulacija imunoregulatorne signalizacije | |
| JP2018532382A5 (enExample) | ||
| JP2017048194A5 (enExample) | ||
| WO2017066484A3 (en) | Nsp10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications | |
| WO2017058892A3 (en) | Methods and compositions for antibody-evading virus vectors | |
| IL288541B (en) | Vaccine against rsv | |
| JP2018520648A5 (enExample) | ||
| HRP20201323T1 (hr) | Protutijela koja se specifično vežu na tl1a | |
| BR112015023140A2 (pt) | proteínas de fusão il-22 fc, método para fabricar a proteína de fusão il-22 fc monomérica, composição, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar uma proteína de fusão il-22 fc, composições farmacêuticas e usos de uma composição farmacêutica | |
| JP2015525217A5 (enExample) | ||
| RU2015142245A (ru) | Иммуномодифицирующие частицы для лечения воспаления | |
| PE20190845A1 (es) | Metodos para determinar resistencia a terapia de receptor de androgeno | |
| Roderfeld et al. | Bone marrow transplantation improves hepatic fibrosis in Abcb4−/− mice via Th1 response and matrix metalloproteinase activity | |
| JP2015519878A5 (enExample) | ||
| Criscitiello et al. | Deiminated proteins in extracellular vesicles and serum of llama (Lama glama)—Novel insights into camelid immunity | |
| JP2016527891A5 (enExample) | ||
| JP2020520680A5 (enExample) | ||
| JP2016508143A5 (enExample) | ||
| WO2016100328A8 (en) | Novel tilapia virus and uses thereof | |
| EA201890856A1 (ru) | Улучшенные транспортные молекулы модулярного антигена и их применение у животных | |
| JP2014504297A5 (enExample) | ||
| MA32770B1 (fr) | Anticorps anti-peptides igf-1/e humain modifie |